Conditioning following powder micronization: influence on particle growth of salbutamol sulfate.

Drug Dev Ind Pharm

Institute of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg-University, Mainz, Germany.

Published: November 2003

Micronization is a high-energy process that induces changes in the crystallinity of materials. As a result, the crystalline structures on the particles' surface are being destroyed and amorphous areas are formed. After micronization of salbutamol sulfate to be used in dry powder inhalers, only small amounts of amorphous material are produced. Nevertheless, even these small amounts can have important effects on the physical stability of the powder. The amorphous state is thermodynamically unstable and tends to convert to the stable, crystalline state. The recrystallization process of disordered regions on the particles' surface leads to particle growth of milled particles. In this case, bridges of solid material are being formed between the individual particles, which leads to particle growth. This is an undesirable process, because particles for pulmonary administration are designed to range between 1 and 10 microm in diameter to exert respirative effect. In the present investigation, salbutamol sulfate is micronized by an air jet mill, and the generated products are exposed to different conditions. Thereafter, the best possible conditioning parameters and storage conditions for the micronized salbutamol sulfate are worked out and rated. The aim of this treatise is to demonstrate the importance of conditioning following micronization.

Download full-text PDF

Source
http://dx.doi.org/10.1081/ddc-120025865DOI Listing

Publication Analysis

Top Keywords

salbutamol sulfate
16
particle growth
12
particles' surface
8
small amounts
8
leads particle
8
conditioning powder
4
micronization
4
powder micronization
4
micronization influence
4
influence particle
4

Similar Publications

To reduce chronic school absenteeism and morbidity and mortality among school-aged children, the prompt administration of albuterol sulfate in schools remains vital. School-based stock inhaler programs are a practical approach to ensure equitable access to life-saving rescue medication for students. School and community partnerships can potentially strengthen program implementation and fidelity by integrating evidence-based practices into routine care.

View Article and Find Full Text PDF

Stock inhalers are unassigned rescue inhalers available for students who experience asthma symptoms at school. This study sought to understand school nurse and administrator perspectives on school-based asthma management and stock inhaler policy implementation. Twenty-three semistructured interviews were conducted with professionals from five high asthma burdened counties in varied geographic settings.

View Article and Find Full Text PDF

A 3D Model of the Human Lung Airway for Evaluating Permeability of Inhaled Drugs.

ACS Pharmacol Transl Sci

January 2025

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA), Silver Spring, Maryland 20993, United States.

Current in vitro cell-based methods, relying on single cell types, have structural and functional limitations in determining lung drug permeability, which is a contributing factor affecting both local and systemic drug levels. To address this issue, we investigated a 3D human lung airway model generated using a cell culture insert, wherein primary human lung epithelial and endothelial cells were cocultured at an air-liquid interface (ALI). To ensure that the cell culture mimics the physiological and functional characteristics of airway tissue, the model was characterized by evaluating several parameters such as cellular confluency, ciliation, tight junctions, mucus-layer formation, transepithelial electrical resistance, and barrier function through assaying fluorescein isothiocyanate-dextran permeability.

View Article and Find Full Text PDF

The first combination inhaled corticosteroid and short-acting beta₂ agonist (ICS-SABA) was approved by the Food and Drug Administration (FDA) in 2023 for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma exacerbations in patients 18 years of age and older. The recently approved product contains an ICS-albuterol combination. The 2024 Global Initiative for Asthma (GINA) guidelines recommend as-needed ICS-formoterol as the preferred asthma reliever therapy; however, a GINA alternative recommendation is the use of ICS whenever an as-needed (SABA) is used.

View Article and Find Full Text PDF

Objectives: Since 2019 as-needed low-dose ICS-formoterol in a single inhaler has been recommended for treatment of mild asthma in children aged more than 12 years. Alternatively, the use of ICS-albuterol has been proposed in countries where ICS-formoterol is not available or affordable. The aim of the present study was to evaluate the cost-utility of as-needed ICS-albuterol in separate inhalers compared to ICS-formoterol in a single inhaler as reliever therapy in pediatric patients with mild asthma living in Colombia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!